These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 1754609)

  • 1. Extrapyramidal symptoms and their relationship to clinical efficacy under perphenazine treatment. A controlled prospective handwriting-test study in 22 acutely ill schizophrenic patients.
    Gerken A; Wetzel H; Benkert O
    Pharmacopsychiatry; 1991 Jul; 24(4):132-7. PubMed ID: 1754609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term depot neuroleptic treatment with perphenazine decanoate. I. Efficacy and side effects in a 12 month study of 42 drug monitored psychotic patients.
    Knudsen P; Hansen LB; Højholdt K; Larsen NE
    Acta Psychiatr Scand Suppl; 1985; 322():29-40. PubMed ID: 3907279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects.
    Mazure CM; Nelson JC; Jatlow PI; Kincare P; Bowers MB
    J Clin Psychiatry; 1990 Aug; 51(8):330-4. PubMed ID: 2199431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perphenazine decanoate vs. perphenazine enanthate: efficacy and side effects in a 6 week double-blind, comparative study of 50 drug monitored psychotic patients.
    Knudsen P; Hansen LB; Auken G; Waehrens J; Højholdt K; Larsen NE
    Acta Psychiatr Scand Suppl; 1985; 322():15-28. PubMed ID: 3907278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects and side-effects of bromperidol in comparison with other antipsychotic drugs.
    Woggon B
    Acta Psychiatr Belg; 1978; 78(1):155-72. PubMed ID: 347878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects.
    Kinon BJ; Kane JM; Chakos M; Munne R
    Psychopharmacol Bull; 1993; 29(3):365-9. PubMed ID: 7907184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects.
    Hansen LB; Larsen NE; Vestergård P
    Psychopharmacology (Berl); 1981; 74(4):306-9. PubMed ID: 6794071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression.
    Rothschild AJ; Samson JA; Bessette MP; Carter-Campbell JT
    J Clin Psychiatry; 1993 Sep; 54(9):338-42. PubMed ID: 8104930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Results of treatment of schizophrenic and schizoaffective patients with sulpiride (Eglonyl Alkaloid) in comparison with perphenazine (Perfenazin Spofa)].
    Svestka J; Rysánek R; Náhunek K; Cesková E
    Cesk Psychiatr; 1990 Jun; 86(3):145-56. PubMed ID: 2225184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cause of mortality in schizophrenic patients: prospective study of years of a cohort of 150 chronic schizophrenic patients].
    Bralet MC; Yon V; Loas G; Noisette C
    Encephale; 2000; 26(6):32-41. PubMed ID: 11217537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipsychotic efficacy of the dopaminergic autoreceptor agonist EMD 49980 (Roxindol). Results of an open clinical study.
    Klimke A; Klieser E
    Pharmacopsychiatry; 1991 Jul; 24(4):107-12. PubMed ID: 1684439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical effects of clozapine: effect on negative symptoms].
    Llorca PM; Lançon C; Auquier P; Bougerol T
    Encephale; 1996; 22(4):287-92. PubMed ID: 9035984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Psychometric effects of perphenacine below the "neuroleptic threshold" (author's transl)].
    Jacobi P; Maxion HH
    Pharmakopsychiatr Neuropsychopharmakol; 1975 Dec; 8(6):366-74. PubMed ID: 1233531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Initial use of risperidone in the treatment of acutely exacerbated schizophrenic patients--an interim analysis].
    Pajonk FG; Schreiner A; Peters S; Rettig K; Degner D; Rüther E
    Fortschr Neurol Psychiatr; 2003 May; 71(5):249-54. PubMed ID: 12740756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships among clinical response, extrapyramidal syndrome and plasma chlorpromazine and metabolite ratios.
    Sakalis G; Chan TL; Sathananthan G; Schooler N; Goldberg S; Gershon S
    Commun Psychopharmacol; 1977; 1(2):157-66. PubMed ID: 342185
    [No Abstract]   [Full Text] [Related]  

  • 17. Haloperidol plasma level after a test dose as predictor for the clinical response to treatment in acute schizophrenic patients.
    Louza Neto MR; Müller-Spahn F; Rüther E; Scherer J
    Pharmacopsychiatry; 1988 Sep; 21(5):226-31. PubMed ID: 3227054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of the sigma receptor ligand EMD 57445 (panamesine) in patients with schizophrenia: an open clinical trial.
    Huber MT; Gotthardt U; Schreiber W; Krieg JC
    Pharmacopsychiatry; 1999 Mar; 32(2):68-72. PubMed ID: 10333165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Long-term clinical experience with clozapine].
    Gelly F; Chambon O; Marie-Cardine M
    Encephale; 1997; 23(5):385-96. PubMed ID: 9453932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open study with bromperidol (C-C 2489), a new neuroleptic, for the determination of the neuroleptic threshold and the neuroleptic-therapeutic range.
    Haase HJ; Kaumeier S; Schwarz H; Gundel A; Linde OK; Maetz H; Scheel R; Stripf A; Stripf L
    Pharmakopsychiatr Neuropsychopharmakol; 1978 Mar; 11(2):81-5. PubMed ID: 643910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.